You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
未名醫藥(002581.SZ):無償將重組抗CD52人源化單克隆抗體注射液和重組抗CD3人源化單克隆抗體注射液的產權劃轉給北大生物
格隆匯 10-20 21:02

格隆匯 10 月 20日丨未名醫藥(002581.SZ)公佈,公司第四屆董事會第十五次會議決議,審議通過了關於簽訂<藥品技術轉讓合同>的議案

公司基於戰略發展規劃以及經營管理需求全資子公司北大未名(合肥)生物製藥有限公司(“北大生物”)簽訂《藥品技術轉讓合同》,無償將重組抗CD52人源化單克隆抗體注射液和重組抗CD3人源化單克隆抗體注射液的產權劃轉給北大生物。

此次劃轉系內部資源整合不會對合並報表範圍產生影響。本次轉讓對公司的正常經營、未來財務狀況和經營成果不會產生重大影響不會損害公司及股東利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account